Anika Therapeutics, Inc. (ANIK)

Quarterly Report Filed: 2026-04-30

The filing contains extensive XBRL metadata but the actual financial content appears truncated, making it impossible to assess critical metrics like revenue, net income, cash flow, or year-over-year performance changes for Q1 2026.
Multiple operating segments are referenced (Commercial Channel, OEM Channel, Europe, Other Locations) with comparative periods (Q1 2025 vs Q1 2026), but detailed segment performance data is not visible in the provided excerpt.
Significant equity activity is documented including restricted stock units, performance shares, employee stock options, and an ongoing May 2024 share repurchase plan, though specific repurchase activity and dilution impacts cannot be quantified from the truncated filing.
The filing references discontinued operations related to ArthroSurface Incorporated with data through October 2024, suggesting a divestiture occurred, but the financial impact and gain/loss on disposal are not visible in the provided content.

Current Report Filed: 2026-04-29

Two board members (William R. Jellison and Glenn R. Larsen) resigned effective at the 2026 annual meeting, reducing board size from 9 to 7 members; both resignations were non-contentious with no disagreement cited, suggesting planned transitions rather than governance issues.
Q1 2026 financial results were announced on April 29, 2026, with the full press release furnished as an exhibit but not detailed in the 8-K filing itself, limiting immediate visibility into revenue, profitability, or guidance changes.
The company maintains its listing on NASDAQ Global Select Market and is not classified as an emerging growth company, indicating it is a mature public company with established reporting obligations and institutional investor base.

Insider Trading Filed: 2026-03-23

The reporting person, Ian McLeod, was granted 13,097 restricted stock units (RSUs) and 17,663 premium priced stock appreciation rights (PPSARs) on March 19, 2026, indicating ongoing alignment between management and shareholders.
The RSUs vest over time, with the first installment vesting on March 19, 2027, and the PPSARs vest in three annual installments starting on the same date, subject to the reporting person's continued service.
The exercise price of the PPSARs is set at 110% of the fair market value of the company's stock on the grant date, incentivizing the reporting person to drive long-term stock price appreciation.

Insider Trading Filed: 2026-03-11

Insider Ian McLeod, SVP, CAO & Treasurer, exercised 2,197 restricted stock units (RSUs) and sold 639 shares to cover tax withholdings, indicating continued confidence in the company's long-term prospects.
McLeod's total beneficial ownership increased to 18,744 shares, representing a significant stake in the company and alignment with shareholder interests.
The RSU vesting schedule suggests a multi-year equity incentive program designed to retain and motivate key management, which can be viewed positively by investors.

Insider Trading Filed: 2026-03-11

Cheryl R. Blanchard, a director of Anika Therapeutics, Inc. (ANIK), has exercised 20,001 restricted stock units (RSUs) and disposed of 5,871 shares to cover tax withholding obligations.
Blanchard now holds a direct ownership of 211,450 shares of ANIK common stock and an indirect ownership of 11,742 shares through a revocable trust.
The transaction represents the final vesting installment of a 60,004 RSU award granted to Blanchard in March 2023, indicating continued executive involvement and commitment to the company.

Insider Trading Filed: 2026-03-11

The reporting person, David Colleran, is an executive (EVP, General Counsel, Corp Sec) at Anika Therapeutics, Inc. (ANIK) and is engaged in insider trading activities.
Colleran exercised 5,465 restricted stock units (RSUs) and sold 1,919 shares to cover tax withholding, indicating an ongoing equity compensation plan and insider liquidity.
Colleran now holds 53,100 shares of Anika Therapeutics, Inc. common stock, suggesting continued alignment with the company's performance.

Current Report Filed: 2026-02-26

Anika Therapeutics reported its Q4 2025 and full-year 2025 financial results, which investors will want to review closely for signs of revenue growth, margin changes, and guidance updates.
The company announced that its Executive Vice President, General Counsel and Corporate Secretary, David Colleran, will be transitioning out of his role by May 1, 2026, which could signal leadership changes.
Investors should review the details of the Transitional Services and General Release of Claims Agreement between the company and Mr. Colleran to understand the terms of his departure.

Current Report Filed: 2026-01-08

Anika Therapeutics has reaffirmed its 2025 revenue guidance, with the commercial channel expected to grow 12-18% year-over-year and the OEM channel to decline 16-20% year-over-year.
The company is undergoing a leadership transition, with CEO Cheryl R. Blanchard stepping down and being replaced by Steve Griffin as the new President and CEO effective February 1, 2026.
As part of the transition, Blanchard will take on the role of Executive Chair of the Board for 12 months, followed by a 6-month period as a Special Advisor, before remaining as an employee for an additional 6 months.

Important Information